RecruitingNot ApplicableNCT07145515

Enhancing Heart Allograft Function With the OCS Heart System Trial

Enhancing Heart Allograft Function With the OCS Heart System (ENHANCE) Trial


Sponsor

TransMedics

Enrollment

655 participants

Start Date

Jan 1, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

This trial is designed to evaluate the safety and effectiveness of the novel OCS Solution and OCS Functional Enhancer (OFE) to support FDA approval in both DBD and DCD heart transplantation. In addition, this trial will evaluate the performance of the novel OCS Solution and OFE compared to Static Cold Storage (SCS) in DBD heart transplantation to potentially demonstrate superiority.


Eligibility

Min Age: 18 Years

Inclusion Criteria25

  • Part A - DCD Donor Hearts \& DBD Donor Hearts Initially Deemed Unsuitable for Cold Storage (Current Approved Indications):
  • Donor hearts are deemed clinically acceptable for transplantation after physical examination of the donor hearts in the donor chest and/or on the back table in the donor operating room.
  • All DCD donors eligible for functional warm ischemic time criteria ≤ 30 minutes. WIT defined as time from when mean systolic blood pressure (SBP) is <50mmHg (sustained for at least 5 minutes) to aortic cross clamp and administration of old cardioplegia in the donor.
  • DBD donor hearts with an expected cross clamp of ≥ 4 hours
  • DBD donor hearts with any of the following organ quality concerns, regardless of cross clamp time:
  • Donor age ≥ 40 years old
  • Unknown downtime
  • Insignificant CAD
  • LVEF ≤ 50%
  • Donor Exclusion • Moderate to severe aortic incompetence
  • Part B - DBD Donor Hearts Currently Used with Cold Storage (New Indication):
  • Donor hearts are deemed clinically acceptable for transplantation after physical examination of the donor hearts in the donor chest and/or on the back table in the donor operating room.
  • Eligible for randomization to OCS or SCS treatment arms.
  • DBD donor hearts with an expected cross clamp time of < 4 hours.
  • Donor Exclusion
  • Moderate to severe aortic incompetence
  • DBD donor with any of the following organ quality concerns:
  • Donor age ≥ 40 years old
  • Unknown downtime
  • Insignificant CAD
  • LVEF ≤ 50%
  • Recipient Eligibility Criteria (for Part A and B Cohorts)
  • Signed informed consent document and authorization to use and disclose protected health information
  • Heart transplant candidate
  • Age ≥ 18 years old

Exclusion Criteria1

  • Participant in any other interventional clinical or investigational trials/programs that may confound the outcomes of this trial

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEOCS Heart

Preservation of donor hearts with OCS Heart System and novel OCS Solution and OCS Functional Enhancer.

OTHERStatic Cold Storage (SCS)

Preservation of donor hearts with static cold storage.


Locations(8)

University of California San Francisco

San Francisco, California, United States

Tampa General Hospital

Tampa, Florida, United States

Massachusetts General Hospital

Boston, Massachusetts, United States

Mount Sinai

New York, New York, United States

Columbia University Irving Medical Center/ New York Presbyterian Hospital

New York, New York, United States

Westchester Medical Center

Valhalla, New York, United States

Duke University

Durham, North Carolina, United States

Baylor Scott and White

Dallas, Texas, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07145515


Related Trials